

[0012] In one aspect, there is provided Use of a TOR kinase inhibitor in combination with an effective amount of erlotinib or a cytidine analog in the manufacture of a medicament for increasing survival without tumor progression of a patient having advanced non-small cell lung cancer, wherein the TOR kinase inhibitor has the following formula (IV):




(IV) or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein R^1 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R^2 is H, substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl; R^3 is H, or a substituted or unsubstituted C_{1-8} alkyl. In certain examples, provided herein are methods for increasing survival without tumor progression of a patient having advanced non-small cell lung cancer, comprising administering an effective amount of a TOR kinase inhibitor in combination with an effective amount of erlotinib or a cytidine analog to said patient.

[0013] In certain examples, the TOR kinase inhibitor is a compound as described herein.


[0014] In one aspect, the present invention refers to use of a TOR kinase inhibitor in combination with an effective amount of erlotinib or azacitidine in the manufacture of a medicament for treating advanced non-small cell lung cancer, wherein the TOR kinase inhibitor has the following formula (IV):



(IV) or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein R^1 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R^2 is H, substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl; R^3 is H, or a substituted or unsubstituted C_{1-8} alkyl. In another aspect, the present invention refers to use of a TOR kinase inhibitor in combination with an effective amount of erlotinib or azacitidine in the manufacture of a medicament for achieving a Response Evaluation Criteria in Solid Tumors (RECIST 1.1) of complete response, partial response or stable disease in a patient having advanced non-small cell lung cancer, wherein the TOR kinase inhibitor has the following formula (IV):



(IV) or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein R^1 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R^2 is H, substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl; R^3 is H, or a substituted or unsubstituted C_{1-8} alkyl. In a further aspect, the present invention refers to Use of a TOR kinase inhibitor in combination with an effective amount of erlotinib or azacitidine in the manufacture of a medicament for increasing survival without tumor progression of a patient having advanced non-small cell lung cancer, wherein the TOR kinase inhibitor has the following formula (IV):




(IV) or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein R^1 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl; R^2 is H, substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl; R^3 is H, or a substituted or unsubstituted C_{1-8} alkyl.

The present disclosure can be understood more fully by reference to the detailed description and examples, which are intended to exemplify non-limiting embodiments.

What is claimed is:

1. Use of a TOR kinase inhibitor in combination with an effective amount of erlotinib or azacitidine ~~a cytidine analog~~ in the manufacture of a medicament for treating advanced non-small cell lung cancer, wherein the TOR kinase inhibitor has the following formula (IV):



(IV)

or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein:

R^1 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;

R^2 is H, substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl;

R^3 is H, or a substituted or unsubstituted C_{1-8} alkyl.


2. The use of claim 1, wherein a TOR kinase inhibitor is ~~administered~~ used in combination with an effective amount of erlotinib ~~to a patient having advanced non-small cell lung cancer~~.

3. The use of claim 1, wherein a TOR kinase inhibitor is ~~administered~~ used in combination with an effective amount of azacitidine~~a cytidine analog to a patient having advanced non-small cell lung cancer~~.

~~4. The use of claim 3, wherein the cytidine analog is azacitidine~~

~~5.~~4. The use of claim 43, wherein the azacitidine is oral azacitidine.

~~6.~~5. Use of a TOR kinase inhibitor in combination with an effective amount of erlotinib or azacitidine ~~a cytidine analog~~ in the manufacture of a medicament for achieving a Response Evaluation Criteria in Solid Tumors (RECIST 1.1) of complete response, partial response or stable disease in a patient having advanced non-small cell lung cancer, wherein the TOR kinase inhibitor has the following formula (IV):



(IV)

or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein:

R^1 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;

R^2 is H, substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl;

R^3 is H, or a substituted or unsubstituted C_{1-8} alkyl.


~~7.~~6. The use of claim ~~6~~5, wherein a TOR kinase inhibitor is ~~administered~~ used in combination with an effective amount of erlotinib ~~to a patient having advanced non-small cell lung cancer~~.

~~8.~~7. The use of claim ~~6~~5, wherein a TOR kinase inhibitor is ~~administered~~ used in combination with an effective amount of azacitidine ~~a cytidine analog to a patient having advanced non-small cell lung cancer~~.

~~9. The use of claim 8, wherein the cytidine analog is azacitidine.~~

~~10.~~8. The use of claim ~~9~~7, wherein the azacitidine is oral azacitidine.

~~11.~~9. Use of a TOR kinase inhibitor in combination with an effective amount of erlotinib or azacitidine ~~a cytidine analog~~ in the manufacture of a medicament for increasing survival without tumor progression of a patient having advanced non-small cell lung cancer, wherein the TOR kinase inhibitor has the following formula (IV):



(IV)

or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein:

R^1 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;

R^2 is H, substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl;

R^3 is H, or a substituted or unsubstituted C_{1-8} alkyl.

~~12.~~10. The use of claim ~~11~~9, wherein a TOR kinase inhibitor is ~~administered~~ used in combination with an effective amount of erlotinib ~~to a patient having advanced non-small cell lung cancer~~.

~~13.~~11. The use of claim ~~11~~9, wherein a TOR kinase inhibitor is ~~administered~~ used in combination with an effective amount of azacitidine ~~a cytidine analog to a patient having advanced non-small cell lung cancer~~.

~~14. The use of claim 13, wherein the cytidine analog is azacitidine.~~

~~15.~~12. The use of claim ~~14~~11, wherein the azacitidine is oral azacitidine.

~~16.~~13. The use of any one of claims 1 – ~~15~~12, wherein the TOR kinase inhibitor is a compound from Table D.